ParkinsonCanadaV1, Main, Exploration, bibRecord, 003210

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

Identifieur interne : 003210 ( Main/Exploration ); précédent : 003209; suivant : 003211

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

Auteurs : Ali H. Rajput [Canada]

Source :

Parkinsonism and Related Disorders [ 1353-8020 ] ; 2001.

RBID : ISTEX:228254EEB365E41C682D9562F952B60A415634A2

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Cadaver, Child, Disease Progression, Dystonia (drug therapy), Dystonia (pathology), Female, Humans, Levodopa (therapeutic use), Longevity (drug effects), Male, Middle Aged, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (pathology), Parkinsonian Disorders (physiopathology), Retrospective Studies, Substantia Nigra (drug effects), Substantia Nigra (pathology), Survival Analysis, Tremor (drug therapy), Tremor (pathology).
MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug effects : Longevity, Substantia Nigra.
- drug therapy : Dystonia, Parkinsonian Disorders, Tremor.
- pathology : Dystonia, Parkinsonian Disorders, Substantia Nigra, Tremor.
- physiopathology : Parkinsonian Disorders.
- Adolescent, Adult, Aged, Aged, 80 and over, Cadaver, Child, Disease Progression, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Analysis.

Abstract

The primary objective of the study was to determine the effect of levodopa (LD) on human substantia nigra. The study included patients seen at the Movement Disorder Clinic, Saskatoon over a 32 year period. The evidence provided is based on epidemiological observations of 934 consecutive Parkinson syndrome (PS) patients assessed during 22 years and detailed studies of six patients including two autopsies. Life expectancy increased significantly with LD therapy. The prolonged survival was evident when the patients were treated during early stage of the illness. One parkinsonian patient with substantia nigra (SN) pathology who was extensively studied for 30 years, revealed significant slowing of the disease progression while on LD. Three essential tremor patients who received 24kg (26 years), 22kg (21.5 years), and 8.5kg (12.5 years) LD respectively, had no evidence of PS and one autopsy revealed normal SN. Two dopa-responsive dystonia patients who received LD 3kg (11 years) and 17kg (29 years) each had no evidence of PS and one autopsy revealed normal number of SN neurons.These observations indicate that LD is not toxic to human SN and are consistent with salutary effect of the drug on the SN in Parkinson's disease.

Url:

https://api-v5.istex.fr/document/228254EEB365E41C682D9562F952B60A415634A2/fulltext/pdf

DOI: 10.1016/S1353-8020(01)00023-2

Affiliations:

Canada

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa prolongs life expectancy and is non-toxic to substantia nigra</title>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:228254EEB365E41C682D9562F952B60A415634A2</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1016/S1353-8020(01)00023-2</idno>
<idno type="url">https://api-v5.istex.fr/document/228254EEB365E41C682D9562F952B60A415634A2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001683</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001683</idno>
<idno type="wicri:Area/Istex/Curation">001683</idno>
<idno type="wicri:Area/Istex/Checkpoint">001039</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001039</idno>
<idno type="wicri:doubleKey">1353-8020:2001:Rajput A:levodopa:prolongs:life</idno>
<idno type="wicri:Area/Main/Merge">003692</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11489674</idno>
<idno type="wicri:Area/PubMed/Corpus">001552</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001552</idno>
<idno type="wicri:Area/PubMed/Curation">001552</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001552</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001552</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001552</idno>
<idno type="wicri:Area/Ncbi/Merge">000174</idno>
<idno type="wicri:Area/Ncbi/Curation">000174</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000174</idno>
<idno type="wicri:doubleKey">1353-8020:2001:Rajput A:levodopa:prolongs:life</idno>
<idno type="wicri:Area/Main/Merge">003576</idno>
<idno type="wicri:Area/Main/Curation">003210</idno>
<idno type="wicri:Area/Main/Exploration">003210</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa prolongs life expectancy and is non-toxic to substantia nigra</title>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurology Division, Royal University Hospital, 103 Hospital Drive, Saskatoon, SK</wicri:regionArea>
<wicri:noRegion>SK</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Parkinsonism and Related Disorders</title>
<title level="j" type="abbrev">PRD</title>
<idno type="ISSN">1353-8020</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="2001">2001</date>
<biblScope unit="volume">8</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="95">95</biblScope>
<biblScope unit="page" to="100">100</biblScope>
</imprint>
<idno type="ISSN">1353-8020</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1353-8020</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cadaver</term>
<term>Child</term>
<term>Disease Progression</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (pathology)</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Longevity (drug effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonian Disorders (pathology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Retrospective Studies</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (pathology)</term>
<term>Survival Analysis</term>
<term>Tremor (drug therapy)</term>
<term>Tremor (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Longevity</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Parkinsonian Disorders</term>
<term>Tremor</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dystonia</term>
<term>Parkinsonian Disorders</term>
<term>Substantia Nigra</term>
<term>Tremor</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cadaver</term>
<term>Child</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
<term>Survival Analysis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The primary objective of the study was to determine the effect of levodopa (LD) on human substantia nigra. The study included patients seen at the Movement Disorder Clinic, Saskatoon over a 32 year period. The evidence provided is based on epidemiological observations of 934 consecutive Parkinson syndrome (PS) patients assessed during 22 years and detailed studies of six patients including two autopsies. Life expectancy increased significantly with LD therapy. The prolonged survival was evident when the patients were treated during early stage of the illness. One parkinsonian patient with substantia nigra (SN) pathology who was extensively studied for 30 years, revealed significant slowing of the disease progression while on LD. Three essential tremor patients who received 24kg (26 years), 22kg (21.5 years), and 8.5kg (12.5 years) LD respectively, had no evidence of PS and one autopsy revealed normal SN. Two dopa-responsive dystonia patients who received LD 3kg (11 years) and 17kg (29 years) each had no evidence of PS and one autopsy revealed normal number of SN neurons.These observations indicate that LD is not toxic to human SN and are consistent with salutary effect of the drug on the SN in Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</noRegion>
<name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003210 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003210 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:228254EEB365E41C682D9562F952B60A415634A2
   |texte=   Levodopa prolongs life expectancy and is non-toxic to substantia nigra
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.